Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GUTSNASDAQ:ICADNASDAQ:MBOTNASDAQ:NMTC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGUTSFractyl Health$2.00+4.5%$1.69$0.87▼$5.50$96.98M1.85326,805 shs83,659 shsICADicad$3.73-2.2%$3.50$1.18▼$4.02$102.49M1.38421,539 shs31,266 shsMBOTMicrobot Medical$2.41-2.3%$2.52$0.82▼$3.38$87.49M1.141.73 million shs281,268 shsNMTCNeuroOne Medical Technologies$0.68-1.4%$0.61$0.40▼$1.39$35.47M0.63185,586 shs28,796 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGUTSFractyl Health0.00%-11.98%-9.05%+52.80%-64.50%ICADicad0.00%+1.33%-3.79%+70.85%+162.76%MBOTMicrobot Medical0.00%-0.40%-5.73%+45.29%+142.16%NMTCNeuroOne Medical Technologies0.00%+19.79%+10.62%-33.24%-15.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGUTSFractyl Health2.3288 of 5 stars3.52.00.00.03.30.00.0ICADicad0.9742 of 5 stars0.05.00.00.02.70.80.0MBOTMicrobot Medical2.1334 of 5 stars3.52.00.00.03.20.00.6NMTCNeuroOne Medical Technologies1.762 of 5 stars3.53.00.00.00.61.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGUTSFractyl Health 3.00Buy$11.00451.38% UpsideICADicad 2.00HoldN/AN/AMBOTMicrobot Medical 3.00Buy$9.00273.13% UpsideNMTCNeuroOne Medical Technologies 3.00Buy$1.45113.86% UpsideCurrent Analyst Ratings BreakdownLatest NMTC, ICAD, MBOT, and GUTS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2025NMTCNeuroOne Medical TechnologiesLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$1.454/17/2025ICADicadLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/16/2025ICADicadBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral4/16/2025ICADicadCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/15/2025GUTSFractyl HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/10/2025MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGUTSFractyl Health$90K1,085.72N/AN/A$0.59 per share3.38ICADicad$19.53M5.24N/AN/A$1.08 per share3.45MBOTMicrobot MedicalN/AN/AN/AN/A$0.17 per shareN/ANMTCNeuroOne Medical Technologies$3.45M9.79N/AN/A$0.03 per share22.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGUTSFractyl Health-$68.69M-$1.85N/AN/AN/A-73,864.52%-228.66%-76.74%8/13/2025 (Estimated)ICADicad-$5.62M-$0.19N/A∞N/A-26.63%-15.03%-11.77%8/14/2025 (Estimated)MBOTMicrobot Medical-$11.44M-$0.65N/AN/AN/AN/A-110.27%-94.20%8/13/2025 (Estimated)NMTCNeuroOne Medical Technologies-$12.32M-$0.22N/A∞N/A-75.41%-334.64%-124.42%8/13/2025 (Estimated)Latest NMTC, ICAD, MBOT, and GUTS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025MBOTMicrobot Medical-$0.15-$0.08+$0.07-$0.08N/AN/A5/13/2025Q1 2025GUTSFractyl Health-$0.49-$0.49N/A-$0.49N/AN/A5/13/2025Q1 2025ICADicad-$0.0625-$0.02+$0.0425-$0.03$4.54 million$4.87 million5/13/2025Q2 2025NMTCNeuroOne Medical Technologies-$0.09-$0.07+$0.02-$0.07$1.27 billion$1.39 billion3/26/2025Q4 2024MBOTMicrobot Medical-$0.18-$0.20-$0.02-$0.20N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGUTSFractyl HealthN/AN/AN/AN/AN/AICADicadN/AN/AN/AN/AN/AMBOTMicrobot MedicalN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGUTSFractyl Health4.612.502.50ICADicadN/A3.663.57MBOTMicrobot MedicalN/A16.1916.19NMTCNeuroOne Medical TechnologiesN/A2.131.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGUTSFractyl HealthN/AICADicad24.61%MBOTMicrobot Medical16.30%NMTCNeuroOne Medical Technologies16.07%Insider OwnershipCompanyInsider OwnershipGUTSFractyl HealthN/AICADicad10.29%MBOTMicrobot Medical4.74%NMTCNeuroOne Medical Technologies8.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGUTSFractyl Health10248.98 millionN/AN/AICADicad14027.47 million24.64 millionOptionableMBOTMicrobot Medical2036.38 million34.65 millionOptionableNMTCNeuroOne Medical Technologies2049.82 million45.38 millionOptionableNMTC, ICAD, MBOT, and GUTS HeadlinesRecent News About These CompaniesHead-To-Head Review: NeuroOne Medical Technologies (NASDAQ:NMTC) & Biodesix (NASDAQ:BDSX)June 20 at 1:37 AM | americanbankingnews.comNeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate SecretaryJune 3, 2025 | globenewswire.comNeuroOne to Attend MedInvest’s MedTech, AI & Digital Health Conference on June 3-4, 2025May 29, 2025 | uk.finance.yahoo.comNeuroOne to Attend MedInvest's MedTech, AI & Digital Health Conference on June 3-4, 2025May 29, 2025 | globenewswire.comEarnings call transcript: NeuroOne Medical beats EPS expectations in Q1 2025May 15, 2025 | uk.investing.comNeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q2 2025 Earnings Call TranscriptMay 14, 2025 | msn.comNeuroOne Medical Technologies Corp (NMTC) Q2 2025 Earnings Call Highlights: Revenue Surge and ...May 14, 2025 | uk.finance.yahoo.comNeuroOne expects FY25 revenue to reach $8M–$10M as OneRF platform advances and new FDA submission broadens pipelineMay 13, 2025 | msn.comNeuroOne Medical Technologies Corporation (NMTC) Q2 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comNeuroOne® Reports Second Quarter Fiscal Year 2025 Financial Results; Gross Margin Improves Significantly YoY to 55.6%May 13, 2025 | globenewswire.comNeuroOne Medical Technologies Corporation: NeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical AdvisorMay 12, 2025 | finanznachrichten.deNeuroOne Appoints Renowned Neurosurgeon Dr. Parag Patil as Chief Medical AdvisorMay 12, 2025 | globenewswire.comLadenburg Thalmann Initiates Coverage of NeuroOne Medical Technologies (NMTC) with Buy RecommendationMay 6, 2025 | msn.comNeuroOne Medical Announces Participation in The D. Boral Capital Inaugural Global ConferenceMay 5, 2025 | newsfilecorp.comNeuroOne® to Report Second Quarter Fiscal Year 2025 Financial Results on Tuesday, May 13 at 8:30 a.m. Eastern TimeMay 1, 2025 | globenewswire.comNeuroOne completes FDA submission for nerve ablation tech to treat facial painApril 24, 2025 | massdevice.comNeuroOne Medical completes FDA submission for OneRF Ablation System RFApril 24, 2025 | markets.businessinsider.comNeuroOne® Completes FDA Submission for the OneRF® Trigeminal Nerve Ablation System to Treat Facial PainApril 23, 2025 | globenewswire.comNeuroOne Medical Technologies Corporation: NeuroOne Issues Letter to ShareholdersApril 17, 2025 | finanznachrichten.deNeuroOne says tariffs won’t impact business, Zimmer Biomet dealApril 17, 2025 | massdevice.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNMTC, ICAD, MBOT, and GUTS Company DescriptionsFractyl Health NASDAQ:GUTS$2.00 +0.09 (+4.45%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.icad NASDAQ:ICAD$3.73 -0.08 (-2.20%) As of 10:27 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.Microbot Medical NASDAQ:MBOT$2.41 -0.06 (-2.35%) As of 10:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.NeuroOne Medical Technologies NASDAQ:NMTC$0.68 -0.01 (-1.40%) As of 10:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Dan Ives Just Unveiled His AI ETF—Does It Live Up to the Hype? Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
